Opko Health offers large analyst-implied upside, a strong earnings beat record and a technical breakout, but weak quality, high leverage and counterparty concentration on Pfizer keep it a speculative holding.
Thesis pillars
- Weak Quality High Leverage↑Improving
- Large Analyst Upside→Stable
- Consistent Earnings Beats↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 26, 2026
Opko Health, Inc. (OPK) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $1.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody... Read more
Sell if holding. Engine safety override at $1.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Score 5.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Opko Health, Inc.
Latest news
- NEWS OPKO Health Schedules Third Quarter 2026 Earnings Release — fiscal.ai Oct 28, 2026 neutral
- NEWS OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly — fiscal.ai Oct 27, 2026 positive
- NEWS OPKO Biologics Doses First Patient In Its Phase 1/2a Clinical Study Of OPK-8801001 To Treat Acromegaly — benzinga Oct 27, 2026 positive
- NEWS Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp — benzinga Oct 20, 2026 neutral
- NEWS Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4 — benzinga Oct 16, 2026 positive
Generated 2026-10-29T11:14:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicNew York and New Jersey10-K Item 1: 'Our clinical and women's health testing services are concentrated in New York and New Jersey.'
- HIGHcounterpartyPfizer10-K Item 1A: 'Our exclusive worldwide agreement with Pfizer is important to our business.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -12.4%. Quality floor flags this regardless of sector context.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Prior stop was $1.51. Score 5.3/10, moderate confidence.
Analyst target: $3.61 (+122.9% upside). Prior stop was $1.51. Stop-loss: $1.51.
Concentration risk — Geographic: New York and New Jersey; Concentration risk — Counterparty: Pfizer; Quality below floor (2.2 < 4.0).
Opko Health, Inc. trades at a P/E of N/A (forward -4.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover OPK with a consensus score of 3.9/5. Average price target: $4.
What does Opko Health, Inc. do?OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and...
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.